Πλοήγηση ανά Θέμα "chronic kidney disease"

-572 G/C single nucleotide polymorphism of interleukin-6 and sepsis predisposition in chronic renal disease

Panayides A., Ioakeimidou A., Karamouzos V., Antonakos N., Koutelidakis I., Giannikopoulos G., Makaritsis K., Voloudakis N., Toutouzas K., Rovina N., Bristianou M., Damoraki G., Routsi C., Giamarellos-Bourboulis E.J. (2015)

Single nucleotide polymorphisms (SNPs) of interleukin (IL)-6 are associated with the development of chronic renal disease (CRD). Their impact for sepsis in the field of CRD was investigated. One control cohort of 115 ...

B12 deficiency in chronic kidney disease: Early recognition matters

Gavriilaki E., Paschou E., Kalaitzoglou A., Papaioannou G., Sabanis N. (2015)

[No abstract available]

Cognitive function and exercise training for chronic renal disease patients: A literature review

Kaltsatou, A.; Grigoriou, S. S.; Karatzaferi, C.; Giannaki, C. D.; Stefanidis, I.; Sakkas, G. K. (2015)

Objective: Cognitive impairment is very often noted in patients with Chronic Kidney Disease (CKD). Even though, exercise is considered to be a quantifiable activity that improves cognition in animals and humans, it seems ...

Daptomycin use in patients with osteomyelitis: A preliminary report from the EU-CORESM database

Andrew Seaton, R.; Malizos, K. N.; Viale, P.; Gargalianos-Kakolyris, P.; Santantonio, T.; Petrelli, E.; Pathan, R.; Heep, M.; Chaves, R. L. (2013)

Background: Osteomyelitis is a complex and heterogeneous group of infections that require surgical and antimicrobial interventions. Because treatment failure or intolerance is common, new treatment options are needed. ...

Epidemiology and importance of renal dysfunction in heart failure patients

Giamouzis, G.; Kalogeropoulos, A. P.; Butler, J.; Karayannis, G.; Georgiopoulou, V. V.; Skoularigis, J.; Triposkiadis, F. (2013)

Renal dysfunction (RD) is a frequent comorbid condition and a major determinant of outcomes in patients with heart failure (HF). It is likely that the etiology of RD in patients with HF is much more complex than we first ...

Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors

Achimastos A., Alexandrides T., Alexopoulos D., Athyros V., Bargiota A., Bilianou E., Chrysochoou C., Drogari E., Elisaf M., Ganotakis E., Goudevenos I., Ioannidis I., Kolovou G., Kotsis V., Lekakis I., Liberopoulos E., Melidonis A., Nikolaou V., Ntaios G., Papanas N., Pappas S., Pitsavos C., Rallidis L., Richter D., Skoumas I., Tentolouris N., Tousoulis D., Tselepis A., Tsioufis K., Tziakas D., Tziomalos K., Vardas P., Vlachopoulo C., Vlahakos D. (2016)

Two proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab and alirocumab, have recently been approved by both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the ...